Articles related to HEART FAILURE (HF)

Digoxin’s narrow therapeutic window and individual patient variability necessitate careful monitoring and consideration in clinical practice.

The bRIGHT study demonstrates that T-TEER using the TriClip system can lead to sustained TR reduction and quality of life improvements in a diverse, real-world population with advanced tricuspid valve disease.

Rapid optimization of guideline-directed medical therapy in heart failure patients post-discharge was associated with sustained decongestion and improved clinical outcomes at 90 days.

Semaglutide treatment led to more frequent improvement and less frequent deterioration in NYHA functional class compared to placebo in patients with obesity-related HFpEF over 52 weeks.

SGLT-2 inhibitors offer benefits beyond glucose control, potentially addressing the systemic inflammatory components of metabolic diseases like diabetes, heart failure, and gout.

Semaglutide demonstrated a significant reduction in symptoms and weight among heart failure patients with diabetes, highlighted by a 7.3-point greater improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score compared to placebo.